
Pharma-Brief Special 3/2012: At the expense of the poor?
22. November 2012
BUKO Pharma-Kampagne has carefully examined the business behaviour of Bayer Health Care, Boehringer Ingelheim and Baxter in Brazil. Our conclusions: whereas Baxter´s portfolio exclusively comprises rational drugs, the manufacturers Bayer and Boehringer Ingelheim sell a considerable number of nonsensical preparations. Even the majority of the blockbusters declared inventive do not offer advantageous treatment for the patients. They are unaffordable and a waste of scarce resources. The companies examined conduct a large number of research projects in brazil. They are focused on lucrative fields such as cardiovascular diseases, cancer and diabetes – diseases which are increasingly common in Brazil. For neglected diseases, which are also still common in Brazil, the companies don´t show much committment.
Download: Brochure [PDF/2,0 mB]